These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 12653671)

  • 21. Reducing early recurrence with adjuvant aromatase inhibitors: what is the evidence?
    Dixon JM
    Breast; 2008 Aug; 17(4):353-60. PubMed ID: 18490163
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Adjuvant chemotherapy of early stage breast cancer].
    Boér K
    Orv Hetil; 2010 Feb; 151(9):344-53. PubMed ID: 20159750
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Aromatase inhibitors--extending the benefits of adjuvant therapy beyond tamoxifen.
    Smith IE
    Breast; 2004 Dec; 13 Suppl 1():S3-9. PubMed ID: 15585377
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Aromatase inhibitors].
    Krysiak R; Okopień B; Herman ZS
    Pol Arch Med Wewn; 2004 Mar; 111(3):375-84. PubMed ID: 15230221
    [No Abstract]   [Full Text] [Related]  

  • 25. The use of third-generation aromatase inhibitors and tamoxifen in the adjuvant treatment of postmenopausal patients with hormone-dependent breast cancer: evidence based review.
    Poole R; Paridaens R
    Curr Opin Oncol; 2007 Nov; 19(6):564-72. PubMed ID: 17906453
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Duration of adjuvant endocrine therapy of breast cancer: how much is enough?
    Ward JH
    Curr Opin Obstet Gynecol; 2010 Feb; 22(1):51-5. PubMed ID: 19952743
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Progress in systemic adjuvant therapy of early-stage breast cancer.
    Gradishar WJ; O'Regan RM
    Int J Clin Oncol; 2003 Aug; 8(4):239-47. PubMed ID: 12955580
    [TBL] [Abstract][Full Text] [Related]  

  • 28. News on the medical treatment of young women with early-stage HER2-negative breast cancer.
    Lambertini M; Poggio F; Vaglica M; Blondeaux E; Del Mastro L
    Expert Opin Pharmacother; 2016 Aug; 17(12):1643-55. PubMed ID: 27322484
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Aromatase inhibitors and inactivators for breast cancer therapy.
    Lønning PE
    Drugs Aging; 2002; 19(4):277-98. PubMed ID: 12038879
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Where do selective estrogen receptor modulators (SERMs) and aromatase inhibitors (AIs) now fit into breast cancer treatment algorithms?
    Howell A; Howell SJ; Clarke R; Anderson E
    J Steroid Biochem Mol Biol; 2001 Dec; 79(1-5):227-37. PubMed ID: 11850229
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Aromatase inhibitors: therapeutic outlook].
    Namer M
    Bull Cancer; 2000 Dec; 87 Spec No():41-5. PubMed ID: 11250607
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The role of aromatase inhibitors in the adjuvant treatment of breast carcinoma: the M. D. Anderson Cancer Center evidence-based approach.
    Morandi P; Rouzier R; Altundag K; Buzdar AU; Theriault RL; Hortobagyi G
    Cancer; 2004 Oct; 101(7):1482-9. PubMed ID: 15378476
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Biologic basis and evolving role of aromatase inhibitors in the management of invasive carcinoma of the breast.
    Kuerer HM; Buzdar AU; Singletary SE
    J Surg Oncol; 2001 Jun; 77(2):139-47. PubMed ID: 11398169
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Recent advances in the management of primary breast cancers.
    Lu YS; Kuo SH; Huang CS
    J Formos Med Assoc; 2004 Aug; 103(8):579-98. PubMed ID: 15340657
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Aromatase inhibitors as adjuvant therapy for postmenopausal women: a therapeutic advance but many unresolved questions.
    Ligibel JA; Winer EP
    Breast Cancer Res; 2005; 7(6):255-7. PubMed ID: 16457700
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reducing the risk of distant metastases in breast cancer patients: role of aromatase inhibitors.
    Del Mastro L; Clavarezza M; Venturini M
    Cancer Treat Rev; 2007 Dec; 33(8):681-7. PubMed ID: 17850976
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adjuvant therapy of primary breast cancer: a review of key findings from the 7th international conference, St. Gallen, February 2001.
    Aapro MS
    Oncologist; 2001; 6(4):376-85. PubMed ID: 11524557
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The aromatase inhibitors as adjuvant therapy for hormone receptor-positive breast cancer.
    Ligibel JA; Winer EP
    J Natl Compr Canc Netw; 2003 Apr; 1(2):215-21. PubMed ID: 19768880
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tamoxifen resistant and refractory breast cancer: the value of aromatase inhibitors.
    Goss PE; Strasser K
    Drugs; 2002; 62(6):957-66. PubMed ID: 11929341
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Letrozole in breast cancer.
    Shahab N
    N Engl J Med; 2004 Feb; 350(7):727-30; author reply 727-30. PubMed ID: 14971058
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.